m6A Regulator and Potential Drug Response

General Information of the m6A Regulator (ID: REG00012)

Regulator Name	Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1)
Synonyms	IGF2 mRNA-binding protein 1; IMP-1; IMP1; Coding region determinant-binding protein; CRD-BP; IGF-II mRNA-binding protein 1; VICKZ family member 1; Zipcode-binding protein 1; ZBP-1; CRDBP; VICKZ1; ZBP1 Click to Show/Hide
Gene Name	IGF2BP1
Regulator Type	WRITER ERASER READER
Regulator Link	Click to View Full Information of This Regulator

Full List of Target Gene(s) of This m6A Regulator and Corresponding Potential Drug Response(s)

Aldehyde dehydrogenase 1 (ALDH1)

All-trans-retinal [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Aldehyde dehydrogenase 1 (ALDH1) is a therapeutic target for All-trans-retinal. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of All-trans-retinal through regulating the expression of Aldehyde dehydrogenase 1 (ALDH1).	[1], [2]

Decanal [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Aldehyde dehydrogenase 1 (ALDH1) is a therapeutic target for Decanal. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of Decanal through regulating the expression of Aldehyde dehydrogenase 1 (ALDH1).	[1], [2]

Cyclin-dependent kinase 4 (CDK4)

Apremilast [Approved]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for Apremilast. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of Apremilast through regulating the expression of Cyclin-dependent kinase 4 (CDK4).	[3], [4]

LY2835219 [Approved]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for LY2835219. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of LY2835219 through regulating the expression of Cyclin-dependent kinase 4 (CDK4).	[3], [5]

Palbociclib [Approved]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for Palbociclib. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of Palbociclib through regulating the expression of Cyclin-dependent kinase 4 (CDK4).	[3], [6]

Ribociclib Succinate [Approved]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for Ribociclib Succinate. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of Ribociclib Succinate through regulating the expression of Cyclin-dependent kinase 4 (CDK4).	[3], [7]

Trilaciclib [Approved]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for Trilaciclib. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of Trilaciclib through regulating the expression of Cyclin-dependent kinase 4 (CDK4).	[3], [8]

LEE011 [Phase 3]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for LEE011. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of LEE011 through regulating the expression of Cyclin-dependent kinase 4 (CDK4).	[3], [9]

FCN-437 [Phase 1/2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for FCN-437. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of FCN-437 through regulating the expression of Cyclin-dependent kinase 4 (CDK4).	[3], [10]

G1T38 [Phase 2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for G1T38. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of G1T38 through regulating the expression of Cyclin-dependent kinase 4 (CDK4).	[3], [11]

GLR2007 [Phase 1/2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for GLR2007. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of GLR2007 through regulating the expression of Cyclin-dependent kinase 4 (CDK4).	[3], [12]

P-276 [Phase 2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for P-276. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of P-276 through regulating the expression of Cyclin-dependent kinase 4 (CDK4).	[3], [13]

P276-00 [Phase 2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for P276-00. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of P276-00 through regulating the expression of Cyclin-dependent kinase 4 (CDK4).	[3], [14]

Ro 31-7453 [Phase 2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for Ro 31-7453. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of Ro 31-7453 through regulating the expression of Cyclin-dependent kinase 4 (CDK4).	[3], [15]

AG-024322 [Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for AG-024322. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of AG-024322 through regulating the expression of Cyclin-dependent kinase 4 (CDK4).	[3], [15]

FN-1501 [Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for FN-1501. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of FN-1501 through regulating the expression of Cyclin-dependent kinase 4 (CDK4).	[3], [16]

G1T28-1 [Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for G1T28-1. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of G1T28-1 through regulating the expression of Cyclin-dependent kinase 4 (CDK4).	[3], [15]

P1446A-05 [Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for P1446A-05. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of P1446A-05 through regulating the expression of Cyclin-dependent kinase 4 (CDK4).	[3], [4]

PF-07220060 [Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for PF-07220060. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of PF-07220060 through regulating the expression of Cyclin-dependent kinase 4 (CDK4).	[3], [17]

PHA-793887 [Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for PHA-793887. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of PHA-793887 through regulating the expression of Cyclin-dependent kinase 4 (CDK4).	[3], [18]

RGB-286638 [Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for RGB-286638. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of RGB-286638 through regulating the expression of Cyclin-dependent kinase 4 (CDK4).	[3], [12]

INOC-005 [Preclinical]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for INOC-005. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of INOC-005 through regulating the expression of Cyclin-dependent kinase 4 (CDK4).	[3], [12]

1-(1H-Indazol-6-yl)-3-pyridin-2-yl-urea [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for 1-(1H-Indazol-6-yl)-3-pyridin-2-yl-urea. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of 1-(1H-Indazol-6-yl)-3-pyridin-2-yl-urea through regulating the expression of Cyclin-dependent kinase 4 (CDK4).	[3], [19]

1-(7-Hydroxy-naphthalen-1-yl)-3-pyridin-2-yl-urea [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for 1-(7-Hydroxy-naphthalen-1-yl)-3-pyridin-2-yl-urea. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of 1-(7-Hydroxy-naphthalen-1-yl)-3-pyridin-2-yl-urea through regulating the expression of Cyclin-dependent kinase 4 (CDK4).	[3], [19]

1-(9-Oxo-9H-fluoren-4-yl)-3-pyridin-2-yl-urea [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for 1-(9-Oxo-9H-fluoren-4-yl)-3-pyridin-2-yl-urea. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of 1-(9-Oxo-9H-fluoren-4-yl)-3-pyridin-2-yl-urea through regulating the expression of Cyclin-dependent kinase 4 (CDK4).	[3], [20]

1-Pyridin-2-yl-3-quinolin-5-yl-urea [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for 1-Pyridin-2-yl-3-quinolin-5-yl-urea. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of 1-Pyridin-2-yl-3-quinolin-5-yl-urea through regulating the expression of Cyclin-dependent kinase 4 (CDK4).	[3], [19]

10-hydroxy-18-methoxybetaenone [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for 10-hydroxy-18-methoxybetaenone. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of 10-hydroxy-18-methoxybetaenone through regulating the expression of Cyclin-dependent kinase 4 (CDK4).	[3], [15]

3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione through regulating the expression of Cyclin-dependent kinase 4 (CDK4).	[3], [20]

3,4-diphenyl-1H-pyrrole-2,5-dione [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for 3,4-diphenyl-1H-pyrrole-2,5-dione. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of 3,4-diphenyl-1H-pyrrole-2,5-dione through regulating the expression of Cyclin-dependent kinase 4 (CDK4).	[3], [21]

3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione through regulating the expression of Cyclin-dependent kinase 4 (CDK4).	[3], [22]

3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione through regulating the expression of Cyclin-dependent kinase 4 (CDK4).	[3], [20]

Cdk4 inhibitor III [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for Cdk4 inhibitor III. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of Cdk4 inhibitor III through regulating the expression of Cyclin-dependent kinase 4 (CDK4).	[3], [23]

Fascaplysin [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for Fascaplysin. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of Fascaplysin through regulating the expression of Cyclin-dependent kinase 4 (CDK4).	[3], [24]

K00024 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for K00024. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of K00024 through regulating the expression of Cyclin-dependent kinase 4 (CDK4).	[3], [25]

N-(2-(1H-Indol-3-yl)ethyl)biphenyl-4-carboxamide [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for N-(2-(1H-Indol-3-yl)ethyl)biphenyl-4-carboxamide. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of N-(2-(1H-Indol-3-yl)ethyl)biphenyl-4-carboxamide through regulating the expression of Cyclin-dependent kinase 4 (CDK4).	[3], [26]

NSC-625987 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for NSC-625987. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of NSC-625987 through regulating the expression of Cyclin-dependent kinase 4 (CDK4).	[3], [27]

NU-6102 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for NU-6102. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of NU-6102 through regulating the expression of Cyclin-dependent kinase 4 (CDK4).	[3], [28]

NU6140 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for NU6140. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of NU6140 through regulating the expression of Cyclin-dependent kinase 4 (CDK4).	[3], [29]

PYRAZOLOPYRIDAZINE 1 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for PYRAZOLOPYRIDAZINE 1. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of PYRAZOLOPYRIDAZINE 1 through regulating the expression of Cyclin-dependent kinase 4 (CDK4).	[3], [24]

PYRAZOLOPYRIDAZINE 2 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for PYRAZOLOPYRIDAZINE 2. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of PYRAZOLOPYRIDAZINE 2 through regulating the expression of Cyclin-dependent kinase 4 (CDK4).	[3], [19]

Ro-0505124 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for Ro-0505124. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of Ro-0505124 through regulating the expression of Cyclin-dependent kinase 4 (CDK4).	[3], [30]

BAY 10-00394 [Discontinued in Phase 2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for BAY 10-00394. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of BAY 10-00394 through regulating the expression of Cyclin-dependent kinase 4 (CDK4).	[3], [31]

CYC-103 [Terminated]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for CYC-103. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of CYC-103 through regulating the expression of Cyclin-dependent kinase 4 (CDK4).	[3], [23]

PD-0183812 [Terminated]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for PD-0183812. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of PD-0183812 through regulating the expression of Cyclin-dependent kinase 4 (CDK4).	[3], [15]

R547 [Discontinued in Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for R547. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of R547 through regulating the expression of Cyclin-dependent kinase 4 (CDK4).	[3], [12]

ZK 304709 [Discontinued in Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for ZK 304709. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of ZK 304709 through regulating the expression of Cyclin-dependent kinase 4 (CDK4).	[3], [12]

Cystine/glutamate transporter (SLC7A11)

L-glutamic acid [Approved]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Cystine/glutamate transporter (SLC7A11) is a therapeutic target for L-glutamic acid. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of L-glutamic acid through regulating the expression of Cystine/glutamate transporter (SLC7A11).	[32], [33]

SXC-2023 [Phase 2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Cystine/glutamate transporter (SLC7A11) is a therapeutic target for SXC-2023. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of SXC-2023 through regulating the expression of Cystine/glutamate transporter (SLC7A11).	[32], [34]

E2F3 messenger RNA (E2F3 mRNA)

ISIS 114170 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	E2F3 messenger RNA (E2F3 mRNA) is a therapeutic target for ISIS 114170. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of ISIS 114170 through regulating the expression of E2F3 messenger RNA (E2F3 mRNA).	[3], [35]

ISIS 114184 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	E2F3 messenger RNA (E2F3 mRNA) is a therapeutic target for ISIS 114184. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of ISIS 114184 through regulating the expression of E2F3 messenger RNA (E2F3 mRNA).	[3], [35]

ISIS 114197 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	E2F3 messenger RNA (E2F3 mRNA) is a therapeutic target for ISIS 114197. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of ISIS 114197 through regulating the expression of E2F3 messenger RNA (E2F3 mRNA).	[3], [35]

ISIS 114232 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	E2F3 messenger RNA (E2F3 mRNA) is a therapeutic target for ISIS 114232. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of ISIS 114232 through regulating the expression of E2F3 messenger RNA (E2F3 mRNA).	[3], [36]

Enhancer of zeste homolog 2 (EZH2)

Tazemetostat [Approved]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Enhancer of zeste homolog 2 (EZH2) is a therapeutic target for Tazemetostat. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of Tazemetostat through regulating the expression of Enhancer of zeste homolog 2 (EZH2).	[37], [38]

CPI-0209 [Phase 1/2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Enhancer of zeste homolog 2 (EZH2) is a therapeutic target for CPI-0209. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of CPI-0209 through regulating the expression of Enhancer of zeste homolog 2 (EZH2).	[37], [39]

CPI-1205 [Phase 1/2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Enhancer of zeste homolog 2 (EZH2) is a therapeutic target for CPI-1205. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of CPI-1205 through regulating the expression of Enhancer of zeste homolog 2 (EZH2).	[37], [40]

DS-3201b [Phase 2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Enhancer of zeste homolog 2 (EZH2) is a therapeutic target for DS-3201b. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of DS-3201b through regulating the expression of Enhancer of zeste homolog 2 (EZH2).	[37], [41]

SHR2554 [Phase 1/2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Enhancer of zeste homolog 2 (EZH2) is a therapeutic target for SHR2554. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of SHR2554 through regulating the expression of Enhancer of zeste homolog 2 (EZH2).	[37], [42]

DS-3201 [Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Enhancer of zeste homolog 2 (EZH2) is a therapeutic target for DS-3201. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of DS-3201 through regulating the expression of Enhancer of zeste homolog 2 (EZH2).	[37], [43]

GSK2816126 [Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Enhancer of zeste homolog 2 (EZH2) is a therapeutic target for GSK2816126. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of GSK2816126 through regulating the expression of Enhancer of zeste homolog 2 (EZH2).	[13], [37]

HH2853 [Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Enhancer of zeste homolog 2 (EZH2) is a therapeutic target for HH2853. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of HH2853 through regulating the expression of Enhancer of zeste homolog 2 (EZH2).	[13], [37]

PF-06821497 [Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Enhancer of zeste homolog 2 (EZH2) is a therapeutic target for PF-06821497. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of PF-06821497 through regulating the expression of Enhancer of zeste homolog 2 (EZH2).	[37], [44]

EI1 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Enhancer of zeste homolog 2 (EZH2) is a therapeutic target for EI1. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of EI1 through regulating the expression of Enhancer of zeste homolog 2 (EZH2).	[37], [45]

EPZ005687 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Enhancer of zeste homolog 2 (EZH2) is a therapeutic target for EPZ005687. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of EPZ005687 through regulating the expression of Enhancer of zeste homolog 2 (EZH2).	[37], [46]

GSK343 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Enhancer of zeste homolog 2 (EZH2) is a therapeutic target for GSK343. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of GSK343 through regulating the expression of Enhancer of zeste homolog 2 (EZH2).	[37], [47]

MS1943 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Enhancer of zeste homolog 2 (EZH2) is a therapeutic target for MS1943. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of MS1943 through regulating the expression of Enhancer of zeste homolog 2 (EZH2).	[37], [48]

UNC1999 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Enhancer of zeste homolog 2 (EZH2) is a therapeutic target for UNC1999. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of UNC1999 through regulating the expression of Enhancer of zeste homolog 2 (EZH2).	[37], [49]

Fascin (FSCN1)

NP-G2-044 [Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Fascin (FSCN1) is a therapeutic target for NP-G2-044. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of NP-G2-044 through regulating the expression of Fascin (FSCN1).	[50], [51]

G1/S-specific cyclin-D1 (CCND1)

ABT-263 [Phase 3]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	G1/S-specific cyclin-D1 (CCND1) is a therapeutic target for ABT-263. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of ABT-263 through regulating the expression of G1/S-specific cyclin-D1 (CCND1).	[3], [52]

Briciclib [Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	G1/S-specific cyclin-D1 (CCND1) is a therapeutic target for Briciclib. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of Briciclib through regulating the expression of G1/S-specific cyclin-D1 (CCND1).	[3], [13]

3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	G1/S-specific cyclin-D1 (CCND1) is a therapeutic target for 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione through regulating the expression of G1/S-specific cyclin-D1 (CCND1).	[3], [20]

3,4-diphenyl-1H-pyrrole-2,5-dione [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	G1/S-specific cyclin-D1 (CCND1) is a therapeutic target for 3,4-diphenyl-1H-pyrrole-2,5-dione. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of 3,4-diphenyl-1H-pyrrole-2,5-dione through regulating the expression of G1/S-specific cyclin-D1 (CCND1).	[3], [20]

3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	G1/S-specific cyclin-D1 (CCND1) is a therapeutic target for 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione through regulating the expression of G1/S-specific cyclin-D1 (CCND1).	[3], [53]

3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	G1/S-specific cyclin-D1 (CCND1) is a therapeutic target for 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione through regulating the expression of G1/S-specific cyclin-D1 (CCND1).	[3], [20]

7-hydroxycoumarin [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	G1/S-specific cyclin-D1 (CCND1) is a therapeutic target for 7-hydroxycoumarin. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of 7-hydroxycoumarin through regulating the expression of G1/S-specific cyclin-D1 (CCND1).	[3], [28]

Janus kinase 2 (JAK-2)

Baricitinib [Approved]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Janus kinase 2 (JAK-2) is a therapeutic target for Baricitinib. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of Baricitinib through regulating the expression of Janus kinase 2 (JAK-2).	[54], [55]

Fedratinib [Approved]

In total 2 mechanisms lead to this potential drug response		Drug Info
Response Summary	Janus kinase 2 (JAK-2) is a therapeutic target for Fedratinib. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of Fedratinib through regulating the expression of Janus kinase 2 (JAK-2).	[54], [56]
	Janus kinase 2 (JAK-2) is a therapeutic target for Fedratinib. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of Fedratinib through regulating the expression of Janus kinase 2 (JAK-2).	[54], [77]

Ruxolitinib [Approved]

In total 2 mechanisms lead to this potential drug response		Drug Info
Response Summary	Janus kinase 2 (JAK-2) is a therapeutic target for Ruxolitinib. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of Ruxolitinib through regulating the expression of Janus kinase 2 (JAK-2).	[54], [57]
	Janus kinase 2 (JAK-2) is a therapeutic target for Ruxolitinib. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of Ruxolitinib through regulating the expression of Janus kinase 2 (JAK-2).	[54], [61]

CYT-387 [Phase 3]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Janus kinase 2 (JAK-2) is a therapeutic target for CYT-387. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of CYT-387 through regulating the expression of Janus kinase 2 (JAK-2).	[54], [58]

ITF2357 [Phase 3]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Janus kinase 2 (JAK-2) is a therapeutic target for ITF2357. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of ITF2357 through regulating the expression of Janus kinase 2 (JAK-2).	[54], [59]

Pacritinib [Phase 3]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Janus kinase 2 (JAK-2) is a therapeutic target for Pacritinib. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of Pacritinib through regulating the expression of Janus kinase 2 (JAK-2).	[54], [60]

XL019 [Phase 3]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Janus kinase 2 (JAK-2) is a therapeutic target for XL019. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of XL019 through regulating the expression of Janus kinase 2 (JAK-2).	[54], [62]

AZD1480 [Phase 2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Janus kinase 2 (JAK-2) is a therapeutic target for AZD1480. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of AZD1480 through regulating the expression of Janus kinase 2 (JAK-2).	[54], [63]

BMS-911543 [Phase 2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Janus kinase 2 (JAK-2) is a therapeutic target for BMS-911543. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of BMS-911543 through regulating the expression of Janus kinase 2 (JAK-2).	[54], [64]

Cerdulatinib [Phase 2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Janus kinase 2 (JAK-2) is a therapeutic target for Cerdulatinib. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of Cerdulatinib through regulating the expression of Janus kinase 2 (JAK-2).	[54], [65]

CTP-543 [Phase 2]

In total 2 mechanisms lead to this potential drug response		Drug Info
Response Summary	Janus kinase 2 (JAK-2) is a therapeutic target for CTP-543. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of CTP-543 through regulating the expression of Janus kinase 2 (JAK-2).	[54], [66]
	Janus kinase 2 (JAK-2) is a therapeutic target for CTP-543. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of CTP-543 through regulating the expression of Janus kinase 2 (JAK-2).	[54], [62]

INCB039110 [Phase 2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Janus kinase 2 (JAK-2) is a therapeutic target for INCB039110. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of INCB039110 through regulating the expression of Janus kinase 2 (JAK-2).	[54], [67]

LY2784544 [Phase 2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Janus kinase 2 (JAK-2) is a therapeutic target for LY2784544. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of LY2784544 through regulating the expression of Janus kinase 2 (JAK-2).	[54], [68]

NS-018 [Phase 1/2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Janus kinase 2 (JAK-2) is a therapeutic target for NS-018. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of NS-018 through regulating the expression of Janus kinase 2 (JAK-2).	[54], [66]

AC430 [Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Janus kinase 2 (JAK-2) is a therapeutic target for AC430. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of AC430 through regulating the expression of Janus kinase 2 (JAK-2).	[54], [69]

Peginterferon beta [Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Janus kinase 2 (JAK-2) is a therapeutic target for Peginterferon beta. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of Peginterferon beta through regulating the expression of Janus kinase 2 (JAK-2).	[54], [57]

SB-1578 [Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Janus kinase 2 (JAK-2) is a therapeutic target for SB-1578. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of SB-1578 through regulating the expression of Janus kinase 2 (JAK-2).	[54], [70]

1,2,3,4,5,6-hexabromocyclohexane [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Janus kinase 2 (JAK-2) is a therapeutic target for 1,2,3,4,5,6-hexabromocyclohexane. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of 1,2,3,4,5,6-hexabromocyclohexane through regulating the expression of Janus kinase 2 (JAK-2).	[54], [71]

5-phenyl-1H-indazol-3-amine [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Janus kinase 2 (JAK-2) is a therapeutic target for 5-phenyl-1H-indazol-3-amine. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of 5-phenyl-1H-indazol-3-amine through regulating the expression of Janus kinase 2 (JAK-2).	[54], [72]

AMG-JAK2-01 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Janus kinase 2 (JAK-2) is a therapeutic target for AMG-JAK2-01. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of AMG-JAK2-01 through regulating the expression of Janus kinase 2 (JAK-2).	[54], [66]

Atropisomer 1 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Janus kinase 2 (JAK-2) is a therapeutic target for Atropisomer 1. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of Atropisomer 1 through regulating the expression of Janus kinase 2 (JAK-2).	[54], [73]

AZ960 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Janus kinase 2 (JAK-2) is a therapeutic target for AZ960. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of AZ960 through regulating the expression of Janus kinase 2 (JAK-2).	[54], [74]

BVB-808 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Janus kinase 2 (JAK-2) is a therapeutic target for BVB-808. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of BVB-808 through regulating the expression of Janus kinase 2 (JAK-2).	[54], [75]

CMP-6 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Janus kinase 2 (JAK-2) is a therapeutic target for CMP-6. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of CMP-6 through regulating the expression of Janus kinase 2 (JAK-2).	[54], [76]

K-454 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Janus kinase 2 (JAK-2) is a therapeutic target for K-454. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of K-454 through regulating the expression of Janus kinase 2 (JAK-2).	[54], [78]

NSC-1771 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Janus kinase 2 (JAK-2) is a therapeutic target for NSC-1771. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of NSC-1771 through regulating the expression of Janus kinase 2 (JAK-2).	[54], [79]

ON-044580 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Janus kinase 2 (JAK-2) is a therapeutic target for ON-044580. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of ON-044580 through regulating the expression of Janus kinase 2 (JAK-2).	[54], [66]

SGI-1252 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Janus kinase 2 (JAK-2) is a therapeutic target for SGI-1252. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of SGI-1252 through regulating the expression of Janus kinase 2 (JAK-2).	[54], [80]

WHI-P154 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Janus kinase 2 (JAK-2) is a therapeutic target for WHI-P154. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of WHI-P154 through regulating the expression of Janus kinase 2 (JAK-2).	[54], [81]

AG490 [Terminated]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Janus kinase 2 (JAK-2) is a therapeutic target for AG490. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of AG490 through regulating the expression of Janus kinase 2 (JAK-2).	[54], [57]

Leukocyte surface antigen CD47 (CD47)

Hu5F9-G4 [Phase 3]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Leukocyte surface antigen CD47 (CD47) is a therapeutic target for Hu5F9-G4. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of Hu5F9-G4 through regulating the expression of Leukocyte surface antigen CD47 (CD47).	[82], [83]

ALX148 [Phase 1/2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Leukocyte surface antigen CD47 (CD47) is a therapeutic target for ALX148. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of ALX148 through regulating the expression of Leukocyte surface antigen CD47 (CD47).	[82], [84]

AO-176 [Phase 1/2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Leukocyte surface antigen CD47 (CD47) is a therapeutic target for AO-176. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of AO-176 through regulating the expression of Leukocyte surface antigen CD47 (CD47).	[13], [82]

DSP-107 [Phase 1/2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Leukocyte surface antigen CD47 (CD47) is a therapeutic target for DSP-107. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of DSP-107 through regulating the expression of Leukocyte surface antigen CD47 (CD47).	[82], [85]

CC-90002 [Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Leukocyte surface antigen CD47 (CD47) is a therapeutic target for CC-90002. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of CC-90002 through regulating the expression of Leukocyte surface antigen CD47 (CD47).	[82], [86]

IBI188 [Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Leukocyte surface antigen CD47 (CD47) is a therapeutic target for IBI188. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of IBI188 through regulating the expression of Leukocyte surface antigen CD47 (CD47).	[82], [87]

IMC-002 [Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Leukocyte surface antigen CD47 (CD47) is a therapeutic target for IMC-002. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of IMC-002 through regulating the expression of Leukocyte surface antigen CD47 (CD47).	[82], [88]

SL-172154 [Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Leukocyte surface antigen CD47 (CD47) is a therapeutic target for SL-172154. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of SL-172154 through regulating the expression of Leukocyte surface antigen CD47 (CD47).	[13], [82]

TG-1801 [Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Leukocyte surface antigen CD47 (CD47) is a therapeutic target for TG-1801. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of TG-1801 through regulating the expression of Leukocyte surface antigen CD47 (CD47).	[82], [89]

TJC4 [Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Leukocyte surface antigen CD47 (CD47) is a therapeutic target for TJC4. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of TJC4 through regulating the expression of Leukocyte surface antigen CD47 (CD47).	[82], [90]

TTI-621 [Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Leukocyte surface antigen CD47 (CD47) is a therapeutic target for TTI-621. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of TTI-621 through regulating the expression of Leukocyte surface antigen CD47 (CD47).	[82], [91]

TTI-622 [Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Leukocyte surface antigen CD47 (CD47) is a therapeutic target for TTI-622. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of TTI-622 through regulating the expression of Leukocyte surface antigen CD47 (CD47).	[82], [92]

ZL-1201 [Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Leukocyte surface antigen CD47 (CD47) is a therapeutic target for ZL-1201. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of ZL-1201 through regulating the expression of Leukocyte surface antigen CD47 (CD47).	[82], [93]

Myb messenger RNA (MYB mRNA)

LR3001 [Phase 2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Myb messenger RNA (MYB mRNA) is a therapeutic target for LR3001. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of LR3001 through regulating the expression of Myb messenger RNA (MYB mRNA).	[1], [94]

Proto-oncogene c-Myc (MYC)

AVI-5126 [Phase 2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Proto-oncogene c-Myc (MYC) is a therapeutic target for AVI-5126. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of AVI-5126 through regulating the expression of Proto-oncogene c-Myc (MYC).	[95], [96]

Resten-NG [Phase 2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Proto-oncogene c-Myc (MYC) is a therapeutic target for Resten-NG. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of Resten-NG through regulating the expression of Proto-oncogene c-Myc (MYC).	[15], [95]

TWS-119 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Proto-oncogene c-Myc (MYC) is a therapeutic target for TWS-119. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of TWS-119 through regulating the expression of Proto-oncogene c-Myc (MYC).	[95], [97]

Signal transducer and activator of transcription 3 (STAT3)

Acitretin [Approved]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for Acitretin. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of Acitretin through regulating the expression of Signal transducer and activator of transcription 3 (STAT3).	[54], [98]

Napabucasin [Phase 3]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for Napabucasin. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of Napabucasin through regulating the expression of Signal transducer and activator of transcription 3 (STAT3).	[54], [99]

Atiprimod [Phase 1/2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for Atiprimod. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of Atiprimod through regulating the expression of Signal transducer and activator of transcription 3 (STAT3).	[54], [100]

GLG-801 [Phase 1/2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for GLG-801. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of GLG-801 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3).	[54], [101]

Golotimod [Phase 2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for Golotimod. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of Golotimod through regulating the expression of Signal transducer and activator of transcription 3 (STAT3).	[13], [54]

IMX-110 [Phase 1/2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for IMX-110. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of IMX-110 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3).	[13], [54]

ISIS-STAT3 [Phase 1/2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for ISIS-STAT3. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of ISIS-STAT3 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3).	[54], [102]

NT219 [Phase 1/2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for NT219. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of NT219 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3).	[54], [103]

OPB-31121 [Phase 1/2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for OPB-31121. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of OPB-31121 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3).	[13], [54]

WP-1066 [Phase 1/2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for WP-1066. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of WP-1066 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3).	[13], [54]

C188-9 [Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for C188-9. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of C188-9 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3).	[54], [104]

DSP-0337 [Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for DSP-0337. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of DSP-0337 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3).	[54], [105]

OPB-111077 [Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for OPB-111077. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of OPB-111077 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3).	[54], [106]

OPB-51602 [Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for OPB-51602. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of OPB-51602 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3).	[54], [107]

TAK-114 [Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for TAK-114. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of TAK-114 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3).	[54], [108]

WP1220 [Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for WP1220. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of WP1220 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3).	[54], [109]

GNF-PF-1399 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for GNF-PF-1399. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of GNF-PF-1399 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3).	[54], [110]

ISIS 113176 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for ISIS 113176. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of ISIS 113176 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3).	[54], [102]

ISIS 113187 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for ISIS 113187. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of ISIS 113187 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3).	[54], [102]

ISIS 113209 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for ISIS 113209. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of ISIS 113209 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3).	[54], [102]

ISIS 113210 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for ISIS 113210. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of ISIS 113210 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3).	[13], [54]

ISIS 17148 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for ISIS 17148. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of ISIS 17148 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3).	[54], [102]

ISIS 17152 [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Signal transducer and activator of transcription 3 (STAT3) is a therapeutic target for ISIS 17152. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of ISIS 17152 through regulating the expression of Signal transducer and activator of transcription 3 (STAT3).	[54], [102]

Thymidine kinase 1 (TK1)

DEOXYCYTIDINE [Approved]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Thymidine kinase 1 (TK1) is a therapeutic target for DEOXYCYTIDINE. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of DEOXYCYTIDINE through regulating the expression of Thymidine kinase 1 (TK1).	[50], [111]

Penciclovir [Approved]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Thymidine kinase 1 (TK1) is a therapeutic target for Penciclovir. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of Penciclovir through regulating the expression of Thymidine kinase 1 (TK1).	[50], [112]

TK-DLI [Preregistration]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Thymidine kinase 1 (TK1) is a therapeutic target for TK-DLI. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of TK-DLI through regulating the expression of Thymidine kinase 1 (TK1).	[50], [111]

FV-100 [Phase 3]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Thymidine kinase 1 (TK1) is a therapeutic target for FV-100. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of FV-100 through regulating the expression of Thymidine kinase 1 (TK1).	[50], [113]

Radiosensitizer gene therapy [Phase 3]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Thymidine kinase 1 (TK1) is a therapeutic target for Radiosensitizer gene therapy. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of Radiosensitizer gene therapy through regulating the expression of Thymidine kinase 1 (TK1).	[50], [114]

RP101 [Phase 2/3]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Thymidine kinase 1 (TK1) is a therapeutic target for RP101. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of RP101 through regulating the expression of Thymidine kinase 1 (TK1).	[50], [111]

HQK-1004 [Phase 2]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Thymidine kinase 1 (TK1) is a therapeutic target for HQK-1004. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of HQK-1004 through regulating the expression of Thymidine kinase 1 (TK1).	[50], [115]

Rilapladib [Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Thymidine kinase 1 (TK1) is a therapeutic target for Rilapladib. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of Rilapladib through regulating the expression of Thymidine kinase 1 (TK1).	[50], [116]

Thymidine kinase-expressing adenovirus and ganciclovir suicide gene therapy [Phase 1]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Thymidine kinase 1 (TK1) is a therapeutic target for Thymidine kinase-expressing adenovirus and ganciclovir suicide gene therapy. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of Thymidine kinase-expressing adenovirus and ganciclovir suicide gene therapy through regulating the expression of Thymidine kinase 1 (TK1).	[50], [117]

(South)-Methanocarba-Thymidine [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Thymidine kinase 1 (TK1) is a therapeutic target for (South)-Methanocarba-Thymidine. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of (South)-Methanocarba-Thymidine through regulating the expression of Thymidine kinase 1 (TK1).	[50], [111]

1-[(Z)-4-(triphenylmethoxy)-2-butenyl]thymine [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Thymidine kinase 1 (TK1) is a therapeutic target for 1-[(Z)-4-(triphenylmethoxy)-2-butenyl]thymine. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of 1-[(Z)-4-(triphenylmethoxy)-2-butenyl]thymine through regulating the expression of Thymidine kinase 1 (TK1).	[50], [118]

1-[2-(2-triphenylmethoxyethoxy)ethyl]thymine [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Thymidine kinase 1 (TK1) is a therapeutic target for 1-[2-(2-triphenylmethoxyethoxy)ethyl]thymine. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of 1-[2-(2-triphenylmethoxyethoxy)ethyl]thymine through regulating the expression of Thymidine kinase 1 (TK1).	[50], [118]

1-[5-(triphenylmethoxy)pentyl]thymine [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Thymidine kinase 1 (TK1) is a therapeutic target for 1-[5-(triphenylmethoxy)pentyl]thymine. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of 1-[5-(triphenylmethoxy)pentyl]thymine through regulating the expression of Thymidine kinase 1 (TK1).	[50], [118]

1-[6-(triphenylmethoxy)hexyl]thymine [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Thymidine kinase 1 (TK1) is a therapeutic target for 1-[6-(triphenylmethoxy)hexyl]thymine. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of 1-[6-(triphenylmethoxy)hexyl]thymine through regulating the expression of Thymidine kinase 1 (TK1).	[50], [118]

1-[7-(triphenylmethoxy)heptyl]thymine [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Thymidine kinase 1 (TK1) is a therapeutic target for 1-[7-(triphenylmethoxy)heptyl]thymine. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of 1-[7-(triphenylmethoxy)heptyl]thymine through regulating the expression of Thymidine kinase 1 (TK1).	[50], [119]

2'-deoxythymidine triphosphate [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Thymidine kinase 1 (TK1) is a therapeutic target for 2'-deoxythymidine triphosphate. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of 2'-deoxythymidine triphosphate through regulating the expression of Thymidine kinase 1 (TK1).	[50], [116]

2'-Deoxyuridine [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Thymidine kinase 1 (TK1) is a therapeutic target for 2'-Deoxyuridine. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of 2'-Deoxyuridine through regulating the expression of Thymidine kinase 1 (TK1).	[50], [120]

3'-(1,2,3-Triazol-1-yl)-3'-deoxy-beta-D-thymidine [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Thymidine kinase 1 (TK1) is a therapeutic target for 3'-(1,2,3-Triazol-1-yl)-3'-deoxy-beta-D-thymidine. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of 3'-(1,2,3-Triazol-1-yl)-3'-deoxy-beta-D-thymidine through regulating the expression of Thymidine kinase 1 (TK1).	[50], [112]

3-(2-propyn-1-yl)thymidine [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Thymidine kinase 1 (TK1) is a therapeutic target for 3-(2-propyn-1-yl)thymidine. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of 3-(2-propyn-1-yl)thymidine through regulating the expression of Thymidine kinase 1 (TK1).	[50], [121]

5-Bromothienyldeoxyuridine [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Thymidine kinase 1 (TK1) is a therapeutic target for 5-Bromothienyldeoxyuridine. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of 5-Bromothienyldeoxyuridine through regulating the expression of Thymidine kinase 1 (TK1).	[50], [111]

5-Iodo-2'-Deoxyuridine-5'-Monophosphate [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Thymidine kinase 1 (TK1) is a therapeutic target for 5-Iodo-2'-Deoxyuridine-5'-Monophosphate. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of 5-Iodo-2'-Deoxyuridine-5'-Monophosphate through regulating the expression of Thymidine kinase 1 (TK1).	[50], [111]

5-propyl-2'-deoxyuridine [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Thymidine kinase 1 (TK1) is a therapeutic target for 5-propyl-2'-deoxyuridine. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of 5-propyl-2'-deoxyuridine through regulating the expression of Thymidine kinase 1 (TK1).	[50], [121]

6-(Dihydroxy-Isobutyl)-Thymine [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Thymidine kinase 1 (TK1) is a therapeutic target for 6-(Dihydroxy-Isobutyl)-Thymine. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of 6-(Dihydroxy-Isobutyl)-Thymine through regulating the expression of Thymidine kinase 1 (TK1).	[50], [111]

6-Hydroxypropylthymine [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Thymidine kinase 1 (TK1) is a therapeutic target for 6-Hydroxypropylthymine. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of 6-Hydroxypropylthymine through regulating the expression of Thymidine kinase 1 (TK1).	[50], [122]

9-(4-Hydroxybutyl)-N2-Phenylguanine [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Thymidine kinase 1 (TK1) is a therapeutic target for 9-(4-Hydroxybutyl)-N2-Phenylguanine. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of 9-(4-Hydroxybutyl)-N2-Phenylguanine through regulating the expression of Thymidine kinase 1 (TK1).	[50], [111]

9-Hydroxypropyladenine, R-Isomer [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Thymidine kinase 1 (TK1) is a therapeutic target for 9-Hydroxypropyladenine, R-Isomer. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of 9-Hydroxypropyladenine, R-Isomer through regulating the expression of Thymidine kinase 1 (TK1).	[50], [111]

9-Hydroxypropyladenine, S-Isomer [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Thymidine kinase 1 (TK1) is a therapeutic target for 9-Hydroxypropyladenine, S-Isomer. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of 9-Hydroxypropyladenine, S-Isomer through regulating the expression of Thymidine kinase 1 (TK1).	[50], [111]

BVDU-MP [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Thymidine kinase 1 (TK1) is a therapeutic target for BVDU-MP. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of BVDU-MP through regulating the expression of Thymidine kinase 1 (TK1).	[50], [123]

Deoxythymidine [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Thymidine kinase 1 (TK1) is a therapeutic target for Deoxythymidine. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of Deoxythymidine through regulating the expression of Thymidine kinase 1 (TK1).	[50], [111]

Edoxudine [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Thymidine kinase 1 (TK1) is a therapeutic target for Edoxudine. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of Edoxudine through regulating the expression of Thymidine kinase 1 (TK1).	[50], [121]

ITdU [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Thymidine kinase 1 (TK1) is a therapeutic target for ITdU. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of ITdU through regulating the expression of Thymidine kinase 1 (TK1).	[50], [118]

L-5-(bromovinyl)deoxyuridine [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Thymidine kinase 1 (TK1) is a therapeutic target for L-5-(bromovinyl)deoxyuridine. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of L-5-(bromovinyl)deoxyuridine through regulating the expression of Thymidine kinase 1 (TK1).	[50], [124]

L-5-iodo-2'-deoxyuridine [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Thymidine kinase 1 (TK1) is a therapeutic target for L-5-iodo-2'-deoxyuridine. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of L-5-iodo-2'-deoxyuridine through regulating the expression of Thymidine kinase 1 (TK1).	[50], [121]

N2-(3-trifluoromethylphenyl)guanine [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Thymidine kinase 1 (TK1) is a therapeutic target for N2-(3-trifluoromethylphenyl)guanine. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of N2-(3-trifluoromethylphenyl)guanine through regulating the expression of Thymidine kinase 1 (TK1).	[50], [121]

P1-(5'-Adenosyl)P5-(5'-Thymidyl)Pentaphosphate [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Thymidine kinase 1 (TK1) is a therapeutic target for P1-(5'-Adenosyl)P5-(5'-Thymidyl)Pentaphosphate. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of P1-(5'-Adenosyl)P5-(5'-Thymidyl)Pentaphosphate through regulating the expression of Thymidine kinase 1 (TK1).	[50], [111]

Thymidine-5'-Phosphate [Investigative]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Thymidine kinase 1 (TK1) is a therapeutic target for Thymidine-5'-Phosphate. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of Thymidine-5'-Phosphate through regulating the expression of Thymidine kinase 1 (TK1).	[50], [111]

Sitimagene ceradenovec [Discontinued in Phase 3]

In total 1 mechanisms lead to this potential drug response		Drug Info
Response Summary	Thymidine kinase 1 (TK1) is a therapeutic target for Sitimagene ceradenovec. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of Sitimagene ceradenovec through regulating the expression of Thymidine kinase 1 (TK1).	[50], [125]

References

Ref 1	RNA-binding protein IGF2BP1 maintains leukemia stem cell properties by regulating HOXB4, MYB, and ALDH1A1. Leukemia. 2020 May;34(5):1354-1363. doi: 10.1038/s41375-019-0656-9. Epub 2019 Nov 25.
Ref 2	Retinoic acid biosynthesis catalyzed by retinal dehydrogenases relies on a rate-limiting conformational transition associated with substrate recognition. Chem Biol Interact. 2013 Feb 25;202(1-3):78-84. doi: 10.1016/j.cbi.2012.11.019. Epub 2012 Dec 7.
Ref 3	Identification of pathology-specific regulators of m(6)A RNA modification to optimize lung cancer management in the context of predictive, preventive, and personalized medicine. EPMA J. 2020 Jul 29;11(3):485-504. doi: 10.1007/s13167-020-00220-3. eCollection 2020 Sep.
Ref 4	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics. 2005 Aug;86(2):127-41. doi: 10.1016/j.ygeno.2005.04.008.
Ref 5	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
Ref 6	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
Ref 7	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014). Expert Opin Ther Pat. 2015;25(8):849-72. doi: 10.1517/13543776.2015.1039984. Epub 2015 May 19.
Ref 8	Agreement signed with Prostagenics to develop prostate cancer treatment. Innovate Oncology, Inc. 2005.
Ref 9	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2017
Ref 10	Clinical pipeline report, company report or official report of Gan & Lee Pharmaceuticals.
Ref 11	Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res. 2013 Nov 15;19(22):6173-82. doi: 10.1158/1078-0432.CCR-13-1675. Epub 2013 Sep 17.
Ref 12	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66. doi: 10.1038/nrd2907.
Ref 13	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 14	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
Ref 15	Liposarcoma: molecular genetics and therapeutics. Sarcoma. 2011;2011:483154. doi: 10.1155/2011/483154. Epub 2010 Dec 27.
Ref 16	Clinical pipeline report, company report or official report of Fochon Pharmaceuticals.
Ref 17	Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia. J Med Chem. 2018 Feb 22;61(4):1499-1518. doi: 10.1021/acs.jmedchem.7b01261. Epub 2018 Feb 12.
Ref 18	ClinicalTrials.gov (NCT04557449) Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (CDK4). U.S. National Institutes of Health.
Ref 19	Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design. J Med Chem. 2001 Dec 20;44(26):4615-27. doi: 10.1021/jm0103256.
Ref 20	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. doi: 10.1021/jm0580297.
Ref 21	Design, synthesis and biological evaluation of new tryptamine and tetrahydro-beta-carboline-based selective inhibitors of CDK4. Bioorg Med Chem. 2008 Aug 15;16(16):7728-39. doi: 10.1016/j.bmc.2008.07.002. Epub 2008 Jul 8.
Ref 22	Dissecting the determinants of cyclin-dependent kinase 2 and cyclin-dependent kinase 4 inhibitor selectivity. J Med Chem. 2006 Sep 7;49(18):5470-7. doi: 10.1021/jm060216x.
Ref 23	Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25. doi: 10.1016/s0165-6147(02)02071-0.
Ref 24	N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular efficacy. J Med Chem. 2004 Sep 9;47(19):4716-30. doi: 10.1021/jm040063i.
Ref 25	The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4. Clin Cancer Res. 1999 Dec;5(12):4279-86.
Ref 26	Anthraquinones and betaenone derivatives from the sponge-associated fungus Microsphaeropsis species: novel inhibitors of protein kinases. J Nat Prod. 2000 Jun;63(6):739-45. doi: 10.1021/np9905259.
Ref 27	5-Arylamino-2-methyl-4,7-dioxobenzothiazoles as inhibitors of cyclin-dependent kinase 4 and cytotoxic agents. Bioorg Med Chem Lett. 2000 Mar 6;10(5):461-4. doi: 10.1016/s0960-894x(00)00014-7.
Ref 28	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9. doi: 10.1021/jm0605740.
Ref 29	Synthesis, structure-activity relationship, and biological studies of indolocarbazoles as potent cyclin D1-CDK4 inhibitors. J Med Chem. 2003 May 22;46(11):2027-30. doi: 10.1021/jm0256169.
Ref 30	Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6486-9. doi: 10.1016/j.bmcl.2008.10.075. Epub 2008 Oct 22.
Ref 31	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1976).
Ref 32	The N6-methyladenosine modification enhances ferroptosis resistance through inhibiting SLC7A11 mRNA deadenylation in hepatoblastoma. Clin Transl Med. 2022 May;12(5):e778. doi: 10.1002/ctm2.778.
Ref 33	The glutamate/cystine antiporter SLC7A11/xCT enhances cancer cell dependency on glucose by exporting glutamate. J Biol Chem. 2017 Aug 25;292(34):14240-14249. doi: 10.1074/jbc.M117.798405. Epub 2017 Jun 19.
Ref 34	US patent application no. 6,498,035, Antisense modulation of MEKK3 expression.
Ref 35	US patent application no. 6,165,791, Antisense inhibition of E2F transcription factor 3 expression.
Ref 36	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 37	IGF2BP1 Promotes Proliferation of Neuroendocrine Neoplasms by Post-Transcriptional Enhancement of EZH2. Cancers (Basel). 2022 Apr 24;14(9):2121. doi: 10.3390/cancers14092121.
Ref 38	EZH2 inhibitors: a patent review (2014-2016). Expert Opin Ther Pat. 2017 Jul;27(7):797-813. doi: 10.1080/13543776.2017.1316976. Epub 2017 Apr 20.
Ref 39	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
Ref 40	ClinicalTrials.gov (NCT04104776) A Study of CPI-0209 in Patients With Advanced Tumors. U.S. National Institutes of Health.
Ref 41	An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1. ACS Chem Biol. 2013;8(6):1324-34. doi: 10.1021/cb400133j. Epub 2013 Apr 24.
Ref 42	Development of new agents for peripheral T-cell lymphoma. Expert Opin Biol Ther. 2019 Mar;19(3):197-209. doi: 10.1080/14712598.2019.1572746. Epub 2019 Jan 29.
Ref 43	Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497). J Med Chem. 2018 Feb 8;61(3):650-665. doi: 10.1021/acs.jmedchem.7b01375. Epub 2017 Dec 27.
Ref 44	Clinical pipeline report, company report or official report of HaiHe Biopharma.
Ref 45	A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol. 2012 Nov;8(11):890-6. doi: 10.1038/nchembio.1084. Epub 2012 Sep 30.
Ref 46	Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2. ACS Med Chem Lett. 2012 Oct 19;3(12):1091-6. doi: 10.1021/ml3003346. eCollection 2012 Dec 13.
Ref 47	Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease. Nat Rev Drug Discov. 2021 Apr;20(4):265-286. doi: 10.1038/s41573-020-00108-x. Epub 2021 Jan 19.
Ref 48	National Cancer Institute Drug Dictionary (drug id 756211).
Ref 49	Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci U S A. 2012 Dec 26;109(52):21360-5. doi: 10.1073/pnas.1210371110. Epub 2012 Dec 10.
Ref 50	Recognition of RNA N(6)-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nat Cell Biol. 2018 Mar;20(3):285-295. doi: 10.1038/s41556-018-0045-z. Epub 2018 Feb 23.
Ref 51	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. doi: 10.1042/0264-6021:3510095.
Ref 52	New selective nonsteroidal aromatase inhibitors: synthesis and inhibitory activity of 2,3 or 5-(alpha-azolylbenzyl)-1H-indoles. Bioorg Med Chem Lett. 1999 Feb 8;9(3):333-6. doi: 10.1016/s0960-894x(98)00737-9.
Ref 53	Clinical pipeline report, company report or official report of Onconova.
Ref 54	N6-Methyladenosine Methyltransferase METTL3 Promotes Angiogenesis and Atherosclerosis by Upregulating the JAK2/STAT3 Pathway via m6A Reader IGF2BP1. Front Cell Dev Biol. 2021 Dec 7;9:731810. doi: 10.3389/fcell.2021.731810. eCollection 2021.
Ref 55	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1. Expert Opin Ther Pat. 2017 Feb;27(2):127-143. doi: 10.1080/13543776.2017.1252753. Epub 2016 Nov 7.
Ref 56	2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. doi: 10.1038/nrd3657.
Ref 57	Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77. doi: 10.1517/13543784.2014.918604. Epub 2014 May 12.
Ref 58	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
Ref 59	National Cancer Institute Drug Dictionary (drug id 609888).
Ref 60	Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis. Leukemia. 2015 Mar;29(3):741-4. doi: 10.1038/leu.2014.306. Epub 2014 Nov 11.
Ref 61	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 62	Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs. 2009 Sep;14(3):471-9. doi: 10.1517/14728210903066809.
Ref 63	Clinical pipeline report, company report or official report of Concert Pharmaceuticals.
Ref 64	Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F. Blood Cancer J. 2013 Apr 12;3(4):e109. doi: 10.1038/bcj.2013.6.
Ref 65	The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell. 2009 Dec 8;16(6):487-97. doi: 10.1016/j.ccr.2009.10.015.
Ref 66	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2048).
Ref 67	Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2. Leukemia. 2012 Feb;26(2):280-8. doi: 10.1038/leu.2011.292. Epub 2011 Oct 21.
Ref 68	Company report (Portola Pharmaceuticals)
Ref 69	Effect of NS-018, a selective JAK2V617F inhibitor, in a murine model of myelofibrosis. Blood Cancer J. 2014 Jan 10;4(1):e174. doi: 10.1038/bcj.2013.73.
Ref 70	Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders. Leukemia. 2008 Jul;22(7):1320-34. doi: 10.1038/leu.2008.133. Epub 2008 Jun 5.
Ref 71	Jak2 tyrosine kinase mediates oxidative stress-induced apoptosis in vascular smooth muscle cells. J Biol Chem. 2004 Aug 13;279(33):34547-52. doi: 10.1074/jbc.M405045200. Epub 2004 May 24.
Ref 72	Janus kinase 2 inhibitors. Synthesis and characterization of a novel polycyclic azaindole. J Med Chem. 2009 Dec 24;52(24):7938-41. doi: 10.1021/jm901383u.
Ref 73	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
Ref 74	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. doi: 10.1093/nar/28.1.235.
Ref 75	Effects of the JAK2 inhibitor, AZ960, on Pim/BAD/BCL-xL survival signaling in the human JAK2 V617F cell line SET-2. J Biol Chem. 2008 Nov 21;283(47):32334-43. doi: 10.1074/jbc.M803813200. Epub 2008 Sep 4.
Ref 76	The specificity of JAK3 kinase inhibitors. Blood. 2008 Feb 15;111(4):2155-7. doi: 10.1182/blood-2007-09-115030. Epub 2007 Dec 19.
Ref 77	The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. Clin Immunol. 2020 May;214:108393. doi: 10.1016/j.clim.2020.108393. Epub 2020 Mar 25.
Ref 78	Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor. Bioorg Med Chem Lett. 2002 Apr 22;12(8):1219-23. doi: 10.1016/s0960-894x(02)00106-3.
Ref 79	Identification of 1,2,3,4,5,6-hexabromocyclohexane as a small molecule inhibitor of jak2 tyrosine kinase autophosphorylation [correction of autophophorylation]. J Med Chem. 2005 Apr 7;48(7):2526-33. doi: 10.1021/jm049470k.
Ref 80	A Non-ATP-Competitive Dual Inhibitor of JAK2 and BCR-ABL Kinases: Elucidation of a Novel Therapeutic Spectrum Based on Substrate Competitive Inhibition. Genes Cancer. 2010 Apr;1(4):331-45. doi: 10.1177/1947601910371337.
Ref 81	Discovery of 1-methyl-1H-imidazole derivatives as potent Jak2 inhibitors. J Med Chem. 2014 Jan 9;57(1):144-58. doi: 10.1021/jm401546n. Epub 2013 Dec 20.
Ref 82	METTL3/IGF2BP1/CD47 contributes to the sublethal heat treatment induced mesenchymal transition in HCC. Biochem Biophys Res Commun. 2021 Mar 26;546:169-177. doi: 10.1016/j.bbrc.2021.01.085. Epub 2021 Feb 12.
Ref 83	A Global Map of Lipid-Binding Proteins and Their Ligandability in Cells. Cell. 2015 Jun 18;161(7):1668-80. doi: 10.1016/j.cell.2015.05.045.
Ref 84	Clinical pipeline report, company report or official report of KAHR Medical.
Ref 85	Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding. Mol Cancer Ther. 2020 Mar;19(3):835-846. doi: 10.1158/1535-7163.MCT-19-1079. Epub 2019 Dec 26.
Ref 86	Clinical pipeline report, company report or official report of TG Theraputics.
Ref 87	National Cancer Institute Drug Dictionary (drug name CC 90002).
Ref 88	Clinical pipeline report, company report or official report of Trillium Therapeutics.
Ref 89	Clinical pipeline report, company report or official report of Shattuck Labs.
Ref 90	Clinical pipeline report, company report or official report of ImmuneOncia Therapeutics.
Ref 91	Clinical pipeline report, company report or official report of I-MAB Biopharma.
Ref 92	Clinical pipeline report, company report or official report of ZAI Lab.
Ref 93	Clinical pipeline report, company report or official report of Innovent Biologics.
Ref 94	ClinicalTrials.gov (NCT03672305) Clinical Study on the Efficacy and Safety of c-Met/PD-L1 CAR-T Cell Injection in the Treatment of HCC
Ref 95	N(6)-methyladenosine (m(6)A) reader IGF2BP1 accelerates gastric cancer aerobic glycolysis in c-Myc-dependent manner. Exp Cell Res. 2022 Aug 1;417(1):113176. doi: 10.1016/j.yexcr.2022.113176. Epub 2022 Apr 27.
Ref 96	Local delivery of c-myc neutrally charged antisense oligonucleotides with transport catheter inhibits myointimal hyperplasia and positively affects vascular remodeling in the rabbit balloon injury model. Catheter Cardiovasc Interv. 2001 Oct;54(2):247-56. doi: 10.1002/ccd.1277.
Ref 97	Anti-ageing pipeline starts to mature. Nat Rev Drug Discov. 2018 Sep;17(9):609-612. doi: 10.1038/nrd.2018.134. Epub 2018 Aug 3.
Ref 98	A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
Ref 99	[Effects of acitretin on the expression of signaling pathway-related genes in epidermal squamous-cell carcinoma cells]. Zhonghua Zhong Liu Za Zhi. 2006 Jan;28(1):21-4.
Ref 100	OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells. Cancer Lett. 2013 Jul 10;335(1):145-52. doi: 10.1016/j.canlet.2013.02.010. Epub 2013 Feb 10.
Ref 101	Clinical pipeline report, company report or official report of Purple Biotech.
Ref 102	US patent application no. 7,098,192, Antisense oligonucleotide modulation of STAT3 expression.
Ref 103	National Cancer Institute Drug Dictionary (drug id 617379).
Ref 104	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1768).
Ref 105	Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. doi: 10.1517/14728210802676278.
Ref 106	Napabucasin, a novel STAT3 inhibitor suppresses proliferation, invasion and stemness of glioblastoma cells. J Exp Clin Cancer Res. 2019 Jul 5;38(1):289. doi: 10.1186/s13046-019-1289-6.
Ref 107	Clinical pipeline report, company report or official report of Moleculin Biotech.
Ref 108	Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies. Ann Oncol. 2015 May;26(5):998-1005. doi: 10.1093/annonc/mdv026. Epub 2015 Jan 21.
Ref 109	Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma. Cancer Res Treat. 2019 Apr;51(2):510-518. doi: 10.4143/crt.2018.226. Epub 2018 Jun 13.
Ref 110	Clinical pipeline report, company report or official report of Gastroenterology.
Ref 111	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
Ref 112	Species- or isozyme-specific enzyme inhibitors. 5. Differential effects of thymidine substituents on affinity for rat thymidine kinase isozymes. J Med Chem. 1982 Jun;25(6):644-9. doi: 10.1021/jm00348a007.
Ref 113	Company report (Takara Bio)
Ref 114	Specific recognition of the bicyclic pyrimidine nucleoside analogs, a new class of highly potent and selective inhibitors of varicella-zoster virus (VZV), by the VZV-encoded thymidine kinase. Mol Pharmacol. 2002 Feb;61(2):249-54. doi: 10.1124/mol.61.2.249.
Ref 115	Pronounced antitumor effects and tumor radiosensitization of double suicide gene therapy. Clin Cancer Res. 1997 Nov;3(11):2081-8.
Ref 116	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. doi: 10.1093/nar/gkq1126. Epub 2010 Nov 8.
Ref 117	Induction of the Epstein-Barr virus thymidine kinase gene with concomitant nucleoside antivirals as a therapeutic strategy for Epstein-Barr virus-associated malignancies. Curr Opin Oncol. 2001 Sep;13(5):360-7. doi: 10.1097/00001622-200109000-00008.
Ref 118	N1-substituted thymine derivatives as mitochondrial thymidine kinase (TK-2) inhibitors. J Med Chem. 2006 Dec 28;49(26):7766-73. doi: 10.1021/jm0610550.
Ref 119	Synthesis, in vitro, and in silico evaluation of organometallic technetium and rhenium thymidine complexes with retained substrate activity toward human thymidine kinase type 1. J Med Chem. 2008 Nov 13;51(21):6689-98. doi: 10.1021/jm800530p. Epub 2008 Oct 7.
Ref 120	Sitimagene ceradenovec: a gene-based drug for the treatment of operable high-grade glioma. Future Oncol. 2010 Nov;6(11):1691-710. doi: 10.2217/fon.10.134.
Ref 121	Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate analogs and acyclonucleosides. Antimicrob Agents Chemother. 2007 Jun;51(6):2028-34. doi: 10.1128/AAC.01284-06. Epub 2007 Apr 16.
Ref 122	Crystal structure of varicella zoster virus thymidine kinase. J Biol Chem. 2003 Jul 4;278(27):24680-7. doi: 10.1074/jbc.M302025200. Epub 2003 Apr 9.
Ref 123	Trichomonas vaginalis thymidine kinase: purification, characterization and search for inhibitors. Biochem J. 1998 Aug 15;334 ( Pt 1)(Pt 1):15-22. doi: 10.1042/bj3340015.
Ref 124	3'-[4-Aryl-(1,2,3-triazol-1-yl)]-3'-deoxythymidine analogues as potent and selective inhibitors of human mitochondrial thymidine kinase. J Med Chem. 2010 Apr 8;53(7):2902-12. doi: 10.1021/jm901532h.
Ref 125	Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Hum Gene Ther. 2003 Feb 10;14(3):227-41. doi: 10.1089/10430340360535788.

m6A Regulator and Potential Drug Response

Cite M6AREG

Correspondence

Prof. Feng ZHU

Prof. Shuiping Liu

Visitor Map